AI-driven covalent drug design strategies targeting main protease (m^pro) against SARS-CoV-2: structural insights and molecular mechanisms

References

• Agost-Beltrán, L., de la Hoz-Rodríguez, S., Bou-Iserte, L., Rodríguez, S., Fernández-de-la-Pradilla, A., & González, F. V. (2022). Advances in the development of SARS-CoV-2 Mpro inhibitors. Molecules (Basel, Switzerland), 27(8), 2523. https://doi.org/10.3390/molecules27082523
   PubMed Web of Science ®Google Scholar
• Agrawal, P., Agrawal, C., & Blunden, G. (2022). RETRACTED: artemisia extracts and artemisinin-based antimalarials for COVID-19 management: Could These be effective antivirals for COVID-19 treatment? Molecules (Basel, Switzerland), 27(12), 3828. https://doi.org/10.3390/molecules27123828
   PubMed Web of Science ®Google Scholar
• Akhoon, B. A., Tiwari, H., & Nargotra, A. (2019). In Silico drug design methods for drug repurposing. In In Silico Drug Design (pp. 47–84). Elsevier. https://doi.org/10.1016/B978-0-12-816125-8.00003-1
   Google Scholar
• Anand, K., Palm, G. J., Mesters, J. R., Siddell, S. G., Ziebuhr, J., & Hilgenfeld, R. (2002). Structure of coronavirus main proteinase reveals combination of a chymotrypsin fold with an extra alpha-helical domain. The EMBO Journal, 21(13), 3213–3224. https://doi.org/10.1093/emboj/cdf327
   PubMed Web of Science ®Google Scholar
• Anand, K., Ziebuhr, J., Wadhwani, P., Mesters, J. R., & Hilgenfeld, R. (2003). Coronavirus main proteinase (3CL pro) structure: Basis for design of anti-SARS drugs. Science, 300(5626), 1763–1767. https://doi.org/10.1126/science.1085658
   PubMed Web of Science ®Google Scholar
• Ataba, E., Dorkenoo, A. M., Nguepou, C. T., Bakai, T., Tchadjobo, T., Kadzahlo, K. D., Yakpa, K., & Atcha-Oubou, T. (2022). Potential Emergence of plasmodium resistance to artemisinin induced by the use of artemisia annua for malaria and COVID-19 prevention in Sub-African Region. Acta Parasitologica, 67(1), 55–60. https://doi.org/10.1007/s11686-021-00489-y
   PubMed Web of Science ®Google Scholar
• Bafna, K., Cioffi, C. L., Krug, R. M., & Montelione, G. T. (2022). Structural similarities between SARS-CoV2 3CLpro and other viral proteases suggest potential lead molecules for developing broad spectrum antivirals. Frontiers in Chemistry, 10, 948553. https://doi.org/10.3389/fchem.2022.948553
   PubMed Web of Science ®Google Scholar
• Bai, Y., Ye, F., Feng, Y., Liao, H., Song, H., Qi, J., Gao, G. F., Tan, W., Fu, L., & Shi, Y. (2021). Structural basis for the inhibition of the SARS-CoV-2 main protease by the anti-HCV drug narlaprevir. Signal Transduction and Targeted Therapy, 6(1), 51. https://doi.org/10.1038/s41392-021-00468-9
   PubMed Web of Science ®Google Scholar
• Bayani, F., Hashkavaei, N. S., Arjmand, S., Rezaei, S., Uskoković, V., Alijanianzadeh, M., Uversky, V. N., Ranaei Siadat, S. O., Mozaffari-Jovin, S., & Sefidbakht, Y. (2023). An overview of the vaccine platforms to combat COVID-19 with a focus on the subunit vaccines. Progress in Biophysics and Molecular Biology, 178, 32–49. https://doi.org/10.1016/j.pbiomolbio.2023.02.004
   PubMed Web of Science ®Google Scholar
• Bayani, F., Safaei Hashkavaei, N., Karamian, M. R., Uskoković, V., & Sefidbakht, Y. (2023). In silico design of a multi-epitope vaccine against the spike and the nucleocapsid proteins of the Omicron variant of SARS-CoV-2. Journal of Biomolecular Structure & Dynamics, 41(21), 11748–11762. https://doi.org/10.1080/07391102.2023.2170470
   PubMedGoogle Scholar
• Beigel, J. H., ACTT-1 Study Group Members, Tomashek, K. M., Dodd, L. E., Mehta, A. K., Zingman, B. S., Kalil, A. C., Hohmann, E., Chu, H. Y., Luetkemeyer, A., Kline, S., Lopez de Castilla, D., Finberg, R. W., Dierberg, K., Tapson, V., Hsieh, L., Patterson, T. F., Paredes, R., Sweeney, D. A., Short, W. R., Touloumi, G., Lye, D. C., & Lane, H. C. (2020). Remdesivir for the treatment of Covid-19—final report. The New England Journal of Medicine, 383(19), 1813–1826. https://doi.org/10.1056/NEJMoa2007764
   PubMed Web of Science ®Google Scholar
• Benetel, G., Silva, T. D S., Fagundes, G. M., Welter, K. C., Melo, F. A., Lobo, A. A. G., Muir, J. P., & Bueno, I. C. S. (2022). Essential oils as in vitro ruminal fermentation manipulators to mitigate methane emission by beef cattle grazing tropical grasses. Molecules (Basel, Switzerland), 27(7), 2227. https://doi.org/10.3390/molecules27072227
   PubMed Web of Science ®Google Scholar
• Blanco-González, A., Cabezón, A., Seco-González, A., Conde-Torres, D., Antelo-Riveiro, P., Piñeiro, Á., & Garcia-Fandino, R. (2023). The role of AI in drug discovery: Challenges, opportunities, and strategies. Pharmaceuticals (Basel, Switzerland), 16(6), 891. https://doi.org/10.3390/ph16060891
   PubMedGoogle Scholar
• Bung, N., Krishnan, S. R., Bulusu, G., & Roy, A. (2021). De novo design of new chemical entities for SARS-CoV-2 using artificial intelligence. Future Medicinal Chemistry, 13(6), 575–585. https://doi.org/10.4155/fmc-2020-0262
   PubMed Web of Science ®Google Scholar
• Chan, H. C. S., Shan, H., Dahoun, T., Vogel, H., & Yuan, S. (2019). Advancing drug discovery via artificial intelligence. Trends in Pharmacological Sciences, 40(8), 592–604. https://doi.org/10.1016/j.tips.2019.06.004
   PubMed Web of Science ®Google Scholar
• Che, Y., Jiang, D., Zhang, Y., Zhang, J., Xu, T., Sun, Y., Fan, J., Wang, J., Chang, N., Wu, Y., Yang, S., Xu, L., Ding, J., Hu, C., Huang, Y., Zhang, J., & Yang, K. (2022). Elevated ubiquitination contributes to protective immunity against severe SARS‐CoV‐2 infection. Clinical and Translational Medicine, 12(12), e1103. https://doi.org/10.1002/ctm2.1103
   PubMed Web of Science ®Google Scholar
• Chen, W., Liu, X., Zhang, S., & Chen, S. (2023). Artificial intelligence for drug discovery: Resources, methods, and applications. Molecular Therapy. Nucleic Acids, 31, 691–702. https://doi.org/10.1016/j.omtn.2023.02.019
   PubMedGoogle Scholar
• Chou, K.-C., Wei, D.-Q., & Zhong, W.-Z. (2003). Binding mechanism of coronavirus main proteinase with ligands and its implication to drug design against SARS. Biochemical and Biophysical Research Communications, 308(1), 148–151. https://doi.org/10.1016/S0006-291X(03)01342-1
   PubMed Web of Science ®Google Scholar
• Choudhury, C., Arul Murugan, N., & Priyakumar, U. D. (2022). Structure-based drug repurposing: Traditional and advanced AI/ML-aided methods. Drug Discovery Today, 27(7), 1847–1861. https://doi.org/10.1016/j.drudis.2022.03.006
   PubMed Web of Science ®Google Scholar
• Clemente-Suárez, V. J., Martínez-González, M. B., Benitez-Agudelo, J. C., Navarro-Jiménez, E., Beltran-Velasco, A. I., Ruisoto, P., Diaz Arroyo, E., Laborde-Cárdenas, C. C., & Tornero-Aguilera, J. F. (2021). The Impact of the COVID-19 Pandemic on Mental Disorders. A Critical Review. International Journal of Environmental Research and Public Health, 18(19), 10041. https://doi.org/10.3390/ijerph181910041
   PubMed Web of Science ®Google Scholar
• Dai, W., Zhang, B., Jiang, X.-M., Su, H., Li, J., Zhao, Y., Xie, X., Jin, Z., Peng, J., Liu, F., Li, C., Li, Y., Bai, F., Wang, H., Cheng, X., Cen, X., Hu, S., Yang, X., Wang, J., … Liu, H. (2020). Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease. Science (New York, N.Y.), 368(6497), 1331–1335. https://doi.org/10.1126/science.abb4489
   PubMed Web of Science ®Google Scholar
• Deng, J., Zhou, F., Hou, W., Heybati, K., Ali, S., Chang, O., Silver, Z., Dhivagaran, T., Ramaraju, H. B., Wong, C. Y., Zuo, Q. K., Lapshina, E., & Mellett, M. (2022). Efficacy of lopinavir–ritonavir combination therapy for the treatment of hospitalized COVID-19 patients: A meta-analysis. Future Virology, 17(3), 169–189. https://doi.org/10.2217/fvl-2021-0066
   Web of Science ®Google Scholar
• Duong, C. Q., & Nguyen, P. T. V. (2023). Exploration of SARS-CoV-2 Mpro noncovalent natural inhibitors using structure-based approaches. ACS Omega, 8(7), 6679–6688. https://doi.org/10.1021/acsomega.2c07259
   PubMedGoogle Scholar
• Elend, L., Jacobsen, L., Cofala, T., Prellberg, J., Teusch, T., Kramer, O., & Solov’yov, I. A. (2022). Design of SARS-CoV-2 main protease inhibitors using artificial intelligence and molecular dynamic simulations. Molecules (Basel, Switzerland), 27(13), 4020. https://doi.org/10.3390/molecules27134020
   PubMed Web of Science ®Google Scholar
• Falahi, S., & Kenarkoohi, A. (2022). Host factors and vaccine efficacy: Implications for COVID‐19 vaccines. Journal of Medical Virology, 94(4), 1330–1335. https://doi.org/10.1002/jmv.27485
   PubMed Web of Science ®Google Scholar
• Faridoon, Ng, R., Zhang, G., & Li, J. J. (2023). An update on the discovery and development of reversible covalent inhibitors. Medicinal Chemistry Research: An International Journal for Rapid Communications on Design and Mechanisms of Action of Biologically Active Agents, 32(6), 1039–1062. https://doi.org/10.1007/s00044-023-03065-3
   PubMed Web of Science ®Google Scholar
• Fischer, C., & Feys, J. R. (2023). SARS-CoV-2 Mpro inhibitors: Achieved diversity, developing resistance and future strategies. Future Pharmacology, 3(1), 80–107. https://doi.org/10.3390/futurepharmacol3010006
   Google Scholar
• Gehringer, M., & Laufer, S. A. (2019). Emerging and re-emerging warheads for targeted covalent inhibitors: Applications in medicinal chemistry and chemical biology. Journal of Medicinal Chemistry, 62(12), 5673–5724. https://doi.org/10.1021/acs.jmedchem.8b01153
   PubMed Web of Science ®Google Scholar
• Ghasemlou, A., Uskoković, V., & Sefidbakht, Y. (2023). Exploration of potential inhibitors for SARS‐CoV‐2 Mpro considering its mutants via structure‐based drug design, molecular docking, MD simulations, MM/PBSA, and DFT calculations. Biotechnology and Applied Biochemistry, 70(1), 439–457. https://doi.org/10.1002/bab.2369
   PubMed Web of Science ®Google Scholar
• Ghassemlou, A., Sefidbakht, Y., & Rahmandoust, M. (2021). The main protease of SARS COV-2 and its specific inhibitors. In COVID-19 (pp. 121–147). Springer Singapore. https://doi.org/10.1007/978-981-16-3108-5_4
   Google Scholar
• Gimeno, A., Ojeda-Montes, M., Tomás-Hernández, S., Cereto-Massagué, A., Beltrán-Debón, R., Mulero, M., Pujadas, G., & Garcia-Vallvé, S. (2019). The Light and dark sides of virtual screening: What is there to know? International Journal of Molecular Sciences, 20(6), 1375. https://doi.org/10.3390/ijms20061375
   PubMed Web of Science ®Google Scholar
• Gomes, I. D S., Santana, C. A., Marcolino, L. S., Lima, L. H. F. D., Melo-Minardi, R. C. D., Dias, R. S., de Paula, S. O., & Silveira, S. D A. (2022). Computational prediction of potential inhibitors for SARS-COV-2 main protease based on machine learning, docking, MM-PBSA calculations, and metadynamics. PLOS One, 17(4), e0267471. https://doi.org/10.1371/journal.pone.0267471
   PubMed Web of Science ®Google Scholar
• Gómez-Bombarelli, R., Wei, J. N., Duvenaud, D., Hernández-Lobato, J. M., Sánchez-Lengeling, B., Sheberla, D., Aguilera-Iparraguirre, J., Hirzel, T. D., Adams, R. P., & Aspuru-Guzik, A. (2018). Automatic chemical design using a data-driven continuous representation of molecules. ACS Central Science, 4(2), 268–276. https://doi.org/10.1021/acscentsci.7b00572
   PubMed Web of Science ®Google Scholar
• Gorbalenya, A. E., Snijder, E. J., & Ziebuhr, J. (2000). Virus-encoded proteinases and proteolytic processing in the Nidovirales. The Journal of General Virology, 81(Pt 4), 853–879. https://doi.org/10.1099/0022-1317-81-4-853
   PubMedGoogle Scholar
• Gordon, D. E., Jang, G. M., Bouhaddou, M., Xu, J., Obernier, K., White, K. M., O'Meara, M. J., Rezelj, V. V., Guo, J. Z., Swaney, D. L., Tummino, T. A., Hüttenhain, R., Kaake, R. M., Richards, A. L., Tutuncuoglu, B., Foussard, H., Batra, J., Haas, K., Modak, M., … Krogan, N. J. (2020). A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. Nature, 583(7816), 459–468. https://doi.org/10.1038/s41586-020-2286-9
   PubMed Web of Science ®Google Scholar
• Goyal, B., & Goyal, D. (2020). Targeting the dimerization of the main protease of coronaviruses: A potential broad-spectrum therapeutic strategy. ACS Combinatorial Science, 22(6), 297–305. https://doi.org/10.1021/acscombsci.0c00058
   PubMed Web of Science ®Google Scholar
• Harrer, S., Shah, P., Antony, B., & Hu, J. (2019). Artificial Intelligence for clinical trial design. Trends in Pharmacological Sciences, 40(8), 577–591. https://doi.org/10.1016/j.tips.2019.05.005
   PubMed Web of Science ®Google Scholar
• Hosogaya, N., Nelfinavir Study Group, Miyazaki, T., Fukushige, Y., Takemori, S., Morimoto, S., Yamamoto, H., Hori, M., Kurokawa, T., Kawasaki, Y., Hanawa, M., Fujii, Y., Hanaoka, H., Iwami, S., Watashi, K., Yamagoe, S., Miyazaki, Y., Wakita, T., Izumikawa, K., Yanagihara, K., Mukae, H., & Kohno, S. (2021). Efficacy and safety of nelfinavir in asymptomatic and mild COVID-19 patients: A structured summary of a study protocol for a multicenter, randomized controlled trial. Trials, 22(1), 309. https://doi.org/10.1186/s13063-021-05282-w
   PubMed Web of Science ®Google Scholar
• Hsu, M.-F., Kuo, C.-J., Chang, K.-T., Chang, H.-C., Chou, C.-C., Ko, T.-P., Shr, H.-L., Chang, G.-G., Wang, A. H.-J., & Liang, P.-H. (2005). Mechanism of the maturation process of SARS-CoV 3CL protease. The Journal of Biological Chemistry, 280(35), 31257–31266. https://doi.org/10.1074/jbc.M502577200
   PubMed Web of Science ®Google Scholar
• Hu, Q., Xiong, Y., Zhu, G., Zhang, Y., Zhang, Y., Huang, P., & Ge, G. (2022). The SARS‐CoV‐2 main protease (M pro): Structure, function, and emerging therapies for COVID‐19. MedComm, 3(3), e151. https://doi.org/10.1002/mco2.151
   PubMedGoogle Scholar
• Huang, F., Han, X., Xiao, X., & Zhou, J. (2022). Covalent warheads targeting cysteine residue: The promising approach in drug development. Molecules (Basel, Switzerland), 27(22), 7728. https://doi.org/10.3390/molecules27227728
   PubMed Web of Science ®Google Scholar
• Jacobs, J., Grum-Tokars, V., Zhou, Y., Turlington, M., Saldanha, S. A., Chase, P., Eggler, A., Dawson, E. S., Baez-Santos, Y. M., Tomar, S., Mielech, A. M., Baker, S. C., Lindsley, C. W., Hodder, P., Mesecar, A., & Stauffer, S. R. (2013). Discovery, synthesis, and structure-based optimization of a series of N - (tert -Butyl)-2- (N -arylamido)-2-(pyridin-3-yl) Acetamides (ML188) as potent noncovalent small molecule inhibitors of the severe acute respiratory syndrome coronavirus (SARS-CoV) 3. Journal of Medicinal Chemistry, 56(2), 534–546. https://doi.org/10.1021/jm301580n
   PubMed Web of Science ®Google Scholar
• Jaiswal, G., Yaduvanshi, S., & Kumar, V. (2022). A potential peptide inhibitor of SARS-CoV-2 S and human ACE2 complex. Journal of Biomolecular Structure & Dynamics, 40(14), 6671–6681. https://doi.org/10.1080/07391102.2021.1889665
   PubMed Web of Science ®Google Scholar
• Jin, Z., Du, X., Xu, Y., Deng, Y., Liu, M., Zhao, Y., Zhang, B., Li, X., Zhang, L., Peng, C., Duan, Y., Yu, J., Wang, L., Yang, K., Liu, F., Jiang, R., Yang, X., You, T., Liu, X., … Yang, H. (2020). Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors. Nature, 582(7811), 289–293. https://doi.org/10.1038/s41586-020-2223-y
   PubMed Web of Science ®Google Scholar
• Johnson, T. O., Adegboyega, A. E., Ojo, O. A., Yusuf, A. J., Iwaloye, O., Ugwah-Oguejiofor, C. J., Asomadu, R. O., Chukwuma, I. F., Ejembi, S. A., Ugwuja, E. I., Alotaibi, S. S., Albogami, S. M., Batiha, G. E.-S., Rajab, B. S., & Conte-Junior, C. A. (2022). A computational approach to elucidate the interactions of chemicals from artemisia annua targeted toward SARS-CoV-2 Main protease inhibition for COVID-19 treatment. Frontiers in Medicine, 9, 907583. https://doi.org/10.3389/fmed.2022.907583
   Web of Science ®Google Scholar
• Kashyap, P., Bhardwaj, V. K., Chauhan, M., Chauhan, V., Kumar, A., Purohit, R., Kumar, A., & Kumar, S. (2022). A ricin-based peptide BRIP from Hordeum vulgare inhibits Mpro of SARS-CoV-2. Scientific Reports, 12(1), 12802. https://doi.org/10.1038/s41598-022-15977-y
   PubMed Web of Science ®Google Scholar
• Kim, H., Hwang, Y. S., Kim, M., & Park, S. B. (2021). Recent advances in the development of covalent inhibitors. RSC Medicinal Chemistry, 12(7), 1037–1045. https://doi.org/10.1039/D1MD00068C
   PubMedGoogle Scholar
• Lockbaum, G. J., Reyes, A. C., Lee, J. M., Tilvawala, R., Nalivaika, E. A., Ali, A., Kurt Yilmaz, N., Thompson, P. R., & Schiffer, C. A. (2021). Crystal structure of SARS-CoV-2 main protease in complex with the non-covalent inhibitor ML188. Viruses, 13(2), 174. https://doi.org/10.3390/v13020174
   PubMed Web of Science ®Google Scholar
• Luukkonen, S., van den Maagdenberg, H. W., Emmerich, M. T. M., & van Westen, G. J. P. (2023). Artificial intelligence in multi-objective drug design. Current Opinion in Structural Biology, 79, 102537. https://doi.org/10.1016/j.sbi.2023.102537
   PubMed Web of Science ®Google Scholar
• Ma, C., Sacco, M. D., Hurst, B., Townsend, J. A., Hu, Y., Szeto, T., Zhang, X., Tarbet, B., Marty, M. T., Chen, Y., & Wang, J. (2020). Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease. Cell Research, 30(8), 678–692. https://doi.org/10.1038/s41422-020-0356-z
   PubMed Web of Science ®Google Scholar
• Maghsoudi, S., Taghavi Shahraki, B., Rameh, F., Nazarabi, M., Fatahi, Y., Akhavan, O., Rabiee, M., Mostafavi, E., Lima, E. C., Saeb, M. R., & Rabiee, N. (2022). A review on computer‐aided chemogenomics and drug repositioning for rational < scp > COVID</scp> ‐19 drug discovery. Chemical Biology & Drug Design, 100(5), 699–721. https://doi.org/10.1111/cbdd.14136
   PubMed Web of Science ®Google Scholar
• McCauley, N., & Ala, M. (1992). The use of expert systems in the healthcare industry. Information & Management, 22(4), 227–235. https://doi.org/10.1016/0378-7206(92)90025-B
   Web of Science ®Google Scholar
• Merz, K. M., Ringe, D., & Reynolds, C. H. (2010). Drug design: Structure- and ligand-based approaches. Cambridge University Press.
   Google Scholar
• Miandad, K., Ullah, A., Bashir, K., Khan, S., Abideen, S. A., Shaker, B., Alharbi, M., Alshammari, A., Ali, M., Haleem, A., & Ahmad, S. (2022). Virtual Screening of artemisia annua phytochemicals as potential inhibitors of SARS-CoV-2 main protease enzyme. Molecules (Basel, Switzerland), 27(22), 8103. https://doi.org/10.3390/molecules27228103
   PubMed Web of Science ®Google Scholar
• Miles, J. C., & Walker, A. J. (2006). The potential application of artificial intelligence in transport. IEE Proceedings - Intelligent Transport Systems, 153(3), 183. https://doi.org/10.1049/ip-its:20060014
   Google Scholar
• Na Takuathung, M., Sakuludomkan, W., Khatsri, R., Dukaew, N., Kraivisitkul, N., Ahmadmusa, B., Mahakkanukrauh, C., Wangthaweesap, K., Onin, J., Srichai, S., Buawangpong, N., & Koonrungsesomboon, N. (2022). Adverse effects of angiotensin-converting enzyme inhibitors in humans: A systematic review and meta-analysis of 378 randomized controlled trials. International Journal of Environmental Research and Public Health, 19(14), 8373. https://doi.org/10.3390/ijerph19148373
   PubMed Web of Science ®Google Scholar
• Narayanan, A., Narwal, M., Majowicz, S. A., Varricchio, C., Toner, S. A., Ballatore, C., Brancale, A., Murakami, K. S., & Jose, J. (2022). Identification of SARS-CoV-2 inhibitors targeting Mpro and PLpro using in-cell-protease assay. Communications Biology, 5(1), 169. https://doi.org/10.1038/s42003-022-03090-9
   PubMed Web of Science ®Google Scholar
• Naveed, M., Ahmed, I., Khalid, N., & Mumtaz, A. S. (2014). Bioinformatics based structural characterization of glucose dehydrogenase (gdh) gene and growth promoting activity of Leclercia sp. QAU-66. Brazilian Journal of Microbiology: [Publication of the Brazilian Society for Microbiology]], 45(2), 603–611. https://doi.org/10.1590/S1517-83822014000200031
   PubMed Web of Science ®Google Scholar
• Naveed, M., Mubeen, S., Khan, S., Ahmed, I., Khalid, N., Suleria, H. A. R., Bano, A., & Mumtaz, A. S. (2014). Identification and characterization of rhizospheric microbial diversity by 16S ribosomal RNA gene sequencing. Brazilian Journal of Microbiology : [Publication of the Brazilian Society for Microbiology]], 45(3), 985–993. https://doi.org/10.1590/S1517-83822014000300031
   PubMed Web of Science ®Google Scholar
• Naveed, M., Tehreem, S., Mubeen, S., Nadeem, F., Zafar, F., & Irshad, M. (2016). In-silico analysis of non-synonymous-SNPs of STEAP2: To provoke the progression of prostate cancer. Open Life Sciences, 11(1), 402–416. https://doi.org/10.1515/biol-2016-0054
   Web of Science ®Google Scholar
• Niu, F., Recht, B., Ré, C., & Wright, S. (2011). HOGWILD!: A lock-free approach to parallelizing stochastic gradient descent. NIPS, 24, 693-701.
   Google Scholar
• Njoroge, F. G., Chen, K. X., Shih, N.-Y., & Piwinski, J. J. (2008). Challenges in modern drug discovery: A case study of boceprevir, an HCV Protease inhibitor for the treatment of hepatitis C virus infection. Accounts of Chemical Research, 41(1), 50–59. https://doi.org/10.1021/ar700109k
   PubMed Web of Science ®Google Scholar
• Paciaroni, A., Libera, V., Ripanti, F., Orecchini, A., Petrillo, C., Francisci, D., Schiaroli, E., Sabbatini, S., Gidari, A., Bianconi, E., Macchiarulo, A., Hussain, R., Silvestrini, L., Moretti, P., Belhaj, N., Vercelli, M., Roque, Y., Mariani, P., Comez, L., & Spinozzi, F. (2023). Stabilization of the dimeric state of SARS-CoV-2 main protease by GC376 and nirmatrelvir. International Journal of Molecular Sciences, 24(7), 6062. https://doi.org/10.3390/ijms24076062
   PubMed Web of Science ®Google Scholar
• Parmar, M., Thumar, R., Patel, B., Athar, M., Jha, P. C., & Patel, D. (2023). Structural differences in 3C-like protease (Mpro) from SARS-CoV and SARS-CoV-2: Molecular insights revealed by molecular dynamics simulations. Structural Chemistry, 34(4), 1–18. https://doi.org/10.1007/s11224-022-02089-6
   Web of Science ®Google Scholar
• Pathade, V., Nene, S., Ratnam, S., Khatri, D. K., Raghuvanshi, R. S., Singh, S. B., & Srivastava, S. (2023). Emerging insights of peptide-based nanotherapeutics for effective management of rheumatoid arthritis. Life Sciences, 312, 121257. https://doi.org/10.1016/j.lfs.2022.121257
   PubMed Web of Science ®Google Scholar
• Paul, D., Sanap, G., Shenoy, S., Kalyane, D., Kalia, K., & Tekade, R. K. (2021). Artificial intelligence in drug discovery and development. Drug Discovery Today, 26(1), 80–93. https://doi.org/10.1016/j.drudis.2020.10.010
   PubMed Web of Science ®Google Scholar
• Pillaiyar, T., Manickam, M., Namasivayam, V., Hayashi, Y., & Jung, S.-H. (2016). An overview of Severe Acute Respiratory Syndrome–Coronavirus (SARS-CoV) 3CL protease inhibitors: peptidomimetics and small molecule chemotherapy. Journal of Medicinal Chemistry, 59(14), 6595–6628. https://doi.org/10.1021/acs.jmedchem.5b01461
   PubMed Web of Science ®Google Scholar
• Poduri, R., Joshi, G., & Jagadeesh, G. (2020). Drugs targeting various stages of the SARS-CoV-2 life cycle: Exploring promising drugs for the treatment of Covid-19. Cellular Signalling, 74, 109721. https://doi.org/10.1016/j.cellsig.2020.109721
   PubMed Web of Science ®Google Scholar
• Previti, S., Ettari, R., Calcaterra, E., Di Maro, S., Hammerschmidt, S. J., Müller, C., Ziebuhr, J., Schirmeister, T., Cosconati, S., & Zappalà, M. (2023). Structure-based lead optimization of peptide-based vinyl methyl ketones as SARS-CoV-2 main protease inhibitors. European Journal of Medicinal Chemistry, 247, 115021. https://doi.org/10.1016/j.ejmech.2022.115021
   PubMed Web of Science ®Google Scholar
• Priya, P., Basit, A., & Bandyopadhyay, P. (2023). A strategy to optimize the peptide-based inhibitors against different mutants of the spike protein of SARS-CoV-2. Journal of Biomolecular Structure & Dynamics, 41(13), 6191–6202. https://doi.org/10.1080/07391102.2022.2103587
   PubMedGoogle Scholar
• Ren, F., Ding, X., Zheng, M., Korzinkin, M., Cai, X., Zhu, W., Mantsyzov, A., Aliper, A., Aladinskiy, V., Cao, Z., Kong, S., Long, X., Man Liu, B. H., Liu, Y., Naumov, V., Shneyderman, A., Ozerov, I. V., Wang, J., Pun, F. W., … Zhavoronkov, A. (2023). AlphaFold accelerates artificial intelligence powered drug discovery: Efficient discovery of a novel CDK20 small molecule inhibitor. Chemical Science, 14(6), 1443–1452. https://doi.org/10.1039/D2SC05709C
   PubMed Web of Science ®Google Scholar
• Rezaei, S., Sefidbakht, Y., & Uskoković, V. (2021). Tracking the pipeline: Immunoinformatics and the COVID-19 vaccine design. Briefings in Bioinformatics, 22(6), bbab241. https://doi.org/10.1093/bib/bbab241
   PubMed Web of Science ®Google Scholar
• Rossetti, G. G., Ossorio, M. A., Rempel, S., Kratzel, A., Dionellis, V. S., Barriot, S., Tropia, L., Gorgulla, C., Arthanari, H., Thiel, V., Mohr, P., Gamboni, R., & Halazonetis, T. D. (2022). Non-covalent SARS-CoV-2 Mpro inhibitors developed from in silico screen hits. Scientific Reports, 12(1), 2505. https://doi.org/10.1038/s41598-022-06306-4
   PubMed Web of Science ®Google Scholar
• Roth, G. J., Stanford, N., & Majerus, P. W. (1975). Acetylation of prostaglandin synthase by aspirin. Proceedings of the National Academy of Sciences of the United States of America, 72(8), 3073–3076. https://doi.org/10.1073/pnas.72.8.3073
   PubMed Web of Science ®Google Scholar
• Shiri, F., Pirhadi, S., & Ghasemi, J. B. (2016). Alignment independent 3D-QSAR, quantum calculations and molecular docking of Mer specific tyrosine kinase inhibitors as anticancer drugs. Saudi Pharmaceutical Journal: Spj: The Official Publication of the Saudi Pharmaceutical Society, 24(2), 197–212. https://doi.org/10.1016/j.jsps.2015.03.012
   PubMed Web of Science ®Google Scholar
• Singh, E., Khan, R. J., Jha, R. K., Amera, G. M., Jain, M., Singh, R. P., Muthukumaran, J., & Singh, A. K. (2020). A comprehensive review on promising anti-viral therapeutic candidates identified against main protease from SARS-CoV-2 through various computational methods. Journal of Genetic Engineering and Biotechnology, 18(1), 69. https://doi.org/10.1186/s43141-020-00085-z
   PubMed Web of Science ®Google Scholar
• Singh, J., Petter, R. C., Baillie, T. A., & Whitty, A. (2011). The resurgence of covalent drugs. Nature Reviews. Drug Discovery, 10(4), 307–317. https://doi.org/10.1038/nrd3410
   PubMed Web of Science ®Google Scholar
• Su, H., Yao, S., Zhao, W., Li, M., Liu, J., Shang, W., Xie, H., Ke, C., Gao, M., Yu, K., Liu, H., Shen, J., Tang, W., Zhang, L., Zuo, J., Jiang, H., Bai, F., Wu, Y., Ye, Y., & Xu, Y. (2020). Discovery of baicalin and baicalein as novel, natural product inhibitors of SARS-CoV-2 3CL protease < em > in vitro</em&gt. BioRxiv, 2020.04.13.038687. https://doi.org/10.1101/2020.04.13.038687
   Google Scholar
• Sutanto, F., Konstantinidou, M., & Dömling, A. (2020). Covalent inhibitors: A rational approach to drug discovery. RSC Medicinal Chemistry, 11(8), 876–884. https://doi.org/10.1039/D0MD00154F
   PubMedGoogle Scholar
• Tan, Y. Q., SoMe4Surgery working group Collaborators, Wang, Z., Yap, Q. V., Chan, Y. H., Ho, R. C., Hamid, A. R. A. H., Landaluce-Olavarria, A., Pellino, G., Gauhar, V., Chand, M., Wroclawski, M. L., Hameed, B. Z., Ling, S. K.-K., Sengupta, S., Gallo, G., Chiu, P. K.-F., Tanidir, Y., Tallada, M. P. V., Garcia, B. N., Colleoni, R., Abiddin, Z. A. Z., & Chiong, E. (2023). Psychological health of surgeons in a time of COVID-19. Annals of Surgery, 277(1), 50–56. https://doi.org/10.1097/SLA.0000000000004775
   PubMed Web of Science ®Google Scholar
• Tang, B., He, F., Liu, D., He, F., Wu, T., Fang, M., Niu, Z., Wu, Z., & Xu, D. (2022). AI-Aided design of novel targeted covalent inhibitors against SARS-CoV-2. Biomolecules, 12(6), 746. https://doi.org/10.3390/biom12060746
   PubMed Web of Science ®Google Scholar
• Thiel, V., Ivanov, K. A., Putics, Á., Hertzig, T., Schelle, B., Bayer, S., Weißbrich, B., Snijder, E. J., Rabenau, H., Doerr, H. W., Gorbalenya, A. E., & Ziebuhr, J. (2003). Mechanisms and enzymes involved in SARS coronavirus genome expression. The Journal of General Virology, 84(Pt 9), 2305–2315. https://doi.org/10.1099/vir.0.19424-0
   PubMed Web of Science ®Google Scholar
• Thümmler, L., Lindemann, M., Horn, P. A., Lenz, V., Konik, M., Gäckler, A., Boss, K., Theodoropoulos, F., Besa, V., Taube, C., Brenner, T., Witzke, O., Krawczyk, A., & Rohn, H. (2022). Early treatment with monoclonal antibodies or convalescent plasma reduces mortality in non-vaccinated COVID-19 high-risk patients. Viruses, 15(1), 119. https://doi.org/10.3390/v15010119
   PubMed Web of Science ®Google Scholar
• Ton, A., Gentile, F., Hsing, M., Ban, F., & Cherkasov, A. (2020). Rapid identification of potential inhibitors of SARS‐CoV‐2 main protease by deep docking of 1.3 billion compounds. Molecular Informatics, 39(8), e2000028. https://doi.org/10.1002/minf.202000028
   PubMed Web of Science ®Google Scholar
• Ullrich, S., & Nitsche, C. (2020). The SARS-CoV-2 main protease as drug target. Bioorganic & Medicinal Chemistry Letters, 30(17), 127377. https://doi.org/10.1016/j.bmcl.2020.127377
   PubMed Web of Science ®Google Scholar
• Vane, J. R., & Botting, R. M. (2003). The mechanism of action of aspirin. Thrombosis Research, 110(5-6), 255–258. https://doi.org/10.1016/S0049-3848(03)00379-7
   PubMed Web of Science ®Google Scholar
• Vora, L. K., Gholap, A. D., Jetha, K., Thakur, R. R. S., Solanki, H. K., & Chavda, V. P. (2023). Artificial Intelligence in Pharmaceutical Technology and Drug Delivery Design. Pharmaceutics, 15(7), 1916. https://doi.org/10.3390/pharmaceutics15071916
   PubMed Web of Science ®Google Scholar
• Wang, F., Xu, Z., Ren, L., Tsang, S. Y., & Xue, H. (2008). GABAA receptor subtype selectivity underlying selective anxiolytic effect of baicalin. Neuropharmacology, 55(7), 1231–1237. https://doi.org/10.1016/j.neuropharm.2008.07.040
   PubMed Web of Science ®Google Scholar
• Wang, H., He, S., Deng, W., Zhang, Y., Li, G., Sun, J., Zhao, W., Guo, Y., Yin, Z., Li, D., & Shang, L. (2020). Comprehensive Insights into the Catalytic Mechanism of Middle East Respiratory Syndrome 3C-Like Protease and Severe Acute Respiratory Syndrome 3C-Like Protease. ACS Catalysis, 10(10), 5871–5890. https://doi.org/10.1021/acscatal.0c00110
   PubMed Web of Science ®Google Scholar
• Wang, L., Ding, J., Pan, L., Cao, D., Jiang, H., & Ding, X. (2019). Artificial intelligence facilitates drug design in the big data era. Chemometrics and Intelligent Laboratory Systems, 194, 103850. https://doi.org/10.1016/j.chemolab.2019.103850
   Web of Science ®Google Scholar
• Wang, M., Cao, R., Zhang, L., Yang, X., Liu, J., Xu, M., Shi, Z., Hu, Z., Zhong, W., & Xiao, G. (2020). Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Research, 30(3), 269–271. https://doi.org/10.1038/s41422-020-0282-0
   PubMed Web of Science ®Google Scholar
• Wei, P., Fan, K., Chen, H., Ma, L., Huang, C., Tan, L., Xi, D., Li, C., Liu, Y., Cao, A., & Lai, L. (2006). The N-terminal octapeptide acts as a dimerization inhibitor of SARS coronavirus 3C-like proteinase. Biochemical and Biophysical Research Communications, 339(3), 865–872. https://doi.org/10.1016/j.bbrc.2005.11.102
   PubMed Web of Science ®Google Scholar
• Wilby, K. J., Partovi, N., Ford, J.-A E., Greanya, E. D., & Yoshida, E. M. (2012). Review of Boceprevir and Telaprevir for the Treatment of Chronic Hepatitis C. Canadian Journal of Gastroenterology = Journal Canadien de Gastroenterologie, 26(4), 205–210. https://doi.org/10.1155/2012/751057
   PubMed Web of Science ®Google Scholar
• Worldometer. (2023). Reported cases and deaths. https://www.worldometers.info/coronavirus/
   Google Scholar
• Xia, S., Chan, J. F.-W., Wang, L., Jiao, F., Chik, K. K.-H., Chu, H., Lan, Q., Xu, W., Wang, Q., Wang, C., Yuen, K.-Y., Lu, L., & Jiang, S. (2022). Peptide-based pan-CoV fusion inhibitors maintain high potency against SARS-CoV-2 Omicron variant. Cell Research, 32(4), 404–406. https://doi.org/10.1038/s41422-022-00617-x
   PubMed Web of Science ®Google Scholar
• Xiao, T., Cui, M., Zheng, C., Zhang, P., Ren, S., Bao, J., Gao, D., Sun, R., Wang, M., Lin, J., Zhang, L., Li, M., Li, D., Zhou, H., & Yang, C. (2022). Both baicalein and gallocatechin gallate effectively inhibit SARS-CoV-2 replication by targeting mpro and sepsis in mice. Inflammation, 45(3), 1076–1088. https://doi.org/10.1007/s10753-021-01602-z
   PubMed Web of Science ®Google Scholar
• Xu, H., Faber, C., Uchiki, T., Racca, J., & Dealwis, C. (2006). Structures of eukaryotic ribonucleotide reductase I define gemcitabine diphosphate binding and subunit assembly. Proceedings of the National Academy of Sciences of the United States of America, 103(11), 4028–4033. https://doi.org/10.1073/pnas.0600440103
   PubMed Web of Science ®Google Scholar
• Xue, X., Yu, H., Yang, H., Xue, F., Wu, Z., Shen, W., Li, J., Zhou, Z., Ding, Y., Zhao, Q., Zhang, X. C., Liao, M., Bartlam, M., & Rao, Z. (2008). Structures of Two Coronavirus Main Proteases: Implications for Substrate Binding and Antiviral Drug Design. Journal of Virology, 82(5), 2515–2527. https://doi.org/10.1128/JVI.02114-07
   PubMed Web of Science ®Google Scholar
• Yamamoto, N., Matsuyama, S., Hoshino, T., & Yamamoto, N. (2020). Nelfinavir inhibits replication of severe acute respiratory syndrome coronavirus 2 in vitro. BioRxiv, 2020.04.06.026476. https://doi.org/10.1101/2020.04.06.026476
   Google Scholar
• Yang, H., Xie, W., Xue, X., Yang, K., Ma, J., Liang, W., Zhao, Q., Zhou, Z., Pei, D., Ziebuhr, J., Hilgenfeld, R., Yuen, K. Y., Wong, L., Gao, G., Chen, S., Chen, Z., Ma, D., Bartlam, M., & Rao, Z. (2005). Design of wide-spectrum inhibitors targeting coronavirus main proteases. PLoS Biology, 3(10), e324. https://doi.org/10.1371/journal.pbio.0030324
   PubMed Web of Science ®Google Scholar
• Yang, H., Yang, M., Ding, Y., Liu, Y., Lou, Z., Zhou, Z., Sun, L., Mo, L., Ye, S., Pang, H., Gao, G. F., Anand, K., Bartlam, M., Hilgenfeld, R., & Rao, Z. (2003). The crystal structures of severe acute respiratory syndrome virus main protease and its complex with an inhibitor. Proceedings of the National Academy of Sciences of the United States of America, 100(23), 13190–13195. https://doi.org/10.1073/pnas.1835675100
   PubMed Web of Science ®Google Scholar
• Zhou, X., Zhong, F., Lin, C., Hu, X., Zhang, Y., Xiong, B., Yin, X., Fu, J., He, W., Duan, J., Fu, Y., Zhou, H., McCormick, P. J., Wang, Q., Li, J., & Zhang, J. (2021). Structure of SARS-CoV-2 main protease in the apo state. Science China. Life Sciences, 64(4), 656–659. https://doi.org/10.1007/s11427-020-1791-3
   PubMed Web of Science ®Google Scholar
• Zhou, Y., Wang, F., Tang, J., Nussinov, R., & Cheng, F. (2020). Artificial intelligence in COVID-19 drug repurposing. The Lancet Digital Health, 2(12), e667–e676. https://doi.org/10.1016/S2589-7500(20)30192-8
   PubMedGoogle Scholar